FREDUN PHARMACEUTICALS L (FREDUN) financials

FREDUN PHARMACEUTICALS L (FREDUN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1987, Fredun PharmaceuticalsLtd manufactures & exports healthcare and pharmaceuticals products[1]

  • Market Cap: ₹2,602Cr.
  • Current Price: ₹1,519
  • Stock P/E: 48.6
  • ROE: 15.8%
  • ROCE: 21.5%
  • Book Value: ₹196
  • Dividend Yield: 0.02%
  • 52W High / Low: ₹1,666/454

In Sep 2026, FREDUN PHARMACEUTICALS L (FREDUN) reported sales ₹268 Cr and net profit ₹19 Cr.

Annual TTM: sales ₹870 Cr, net profit ₹54 Cr.

Shareholding: Promoters 43.62% (Sep 2026), FIIs 0.69% (Sep 2026), DIIs 3.43% (Sep 2026), Public 52.25% (Sep 2026), No. of Shareholders 13,502% (Sep 2026).

FREDUN quarterly results (₹ Cr.)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales103167120145161213228268
YoY Sales growth+18%+42%+52%+35%+57%+27%+90%+84%
Expenses89150103123135184195225
Operating Profit1317172226293343
OPM %13%10%14%15%16%14%14%16%
Other Income00000000
Interest5878111499
Depreciation11122344
Profit before tax7891314122130
Tax %25%12%25%25%25%4%36%37%
Net Profit5771010111319
EPS in Rs3.754.984.776.856.516.757.9811.14
Raw PDF————————
FREDUN profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales113134222275348454635870
Sales growth+16%+19%+66%+24%+27%+30%+40%+63%
Expenses104126208247310401544739
Operating Profit881428385391131
OPM %7%6%6%10%11%12%14%15%
Other Income11221240
Interest445914223942
Depreciation222344812
Profit before tax2391821284876
Tax %24%37%26%38%27%26%30%—
Net Profit2261116213354
EPS in Rs1.581.684.777.9511.0814.6520.2532.38
Dividend Payout %14%14%5%3%2%2%1%—
FREDUN balance sheet (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital444555517
Reserves37396492117137273314
Borrowings35405387106166222247
Other Liabilities6579667481179141190
Total Liabilities141162187257308487642768
Fixed Assets313032394753118149
CWIP00000000
Investments00001223
Other Assets110131155218260433522617
Total Assets141162187257308487642768
FREDUN cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1-110-2-14-0-2116
Cash from Investing Activity-5-1-1-4-9-8-6-74
Cash from Financing Activity414-1725626122
Net Cash Flow02-211-2-165
Free Cash Flow-4-12-1-7-24-8-27-57
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit8%-128%2%-17%-52%-1%-43%18%
FREDUN shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters48.93%48.93%48.93%48.93%43.06%44.17%44.57%43.62%
FIIs0.00%0.00%0.00%0.01%0.46%1.06%1.06%0.69%
DIIs1.59%1.59%1.59%1.61%3.48%2.83%2.94%3.43%
Public49.47%49.47%49.49%49.46%53.00%51.94%51.45%52.25%
No. of Shareholders8,1217,9767,9068,1208,7658,3388,90313,502
FREDUN key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days67126112148466814253
Inventory Days24922724296264246267219
Days Payable2052082151011048816171
Cash Conversion Cycle110145139144205225248201
Working Capital Days666511612697927679
ROCE %21%10%10%13%18%17%19%21%
FREDUNUpdated 11 Nov 2026, 2:16

Fredun Pharmaceuticals L

Market Cap

₹2,602Cr.

Current Price

₹1,519

High / Low

₹1,666/454

Stock P/E

48.6

ROE15.8%
ROCE21.5%
Book Value₹196
Face Value₹10.0
Dividend Yield0.02%

About

Incorporated in 1987, Fredun PharmaceuticalsLtd manufactures & exports healthcare and pharmaceuticals products[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days75981319467126112148466814253
Inventory Days1021406817024922724296264246267219
Days Payable1672212243602052082151011048816171
Cash Conversion Cycle1117-24-96110145139144205225248201
Working Capital Days-54-44-3942666511612697927679
ROCE %14%25%18%16%21%10%10%13%18%17%19%21%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of FREDUN PHARMACEUTICALS L (FREDUN)?

The reported market capitalisation for FREDUN PHARMACEUTICALS L (FREDUN) is ₹2,602Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of FREDUN?

The current price shown for FREDUN PHARMACEUTICALS L (FREDUN) on Fincrux is ₹1,519 with a 52-week high/low of ₹1,666/454.

What is the P/E ratio of FREDUN PHARMACEUTICALS L (FREDUN)?

The stock P/E for FREDUN PHARMACEUTICALS L (FREDUN) is 48.6 on Fincrux, with ROE at 15.8% and ROCE at 21.5%.

What were FREDUN latest quarterly results?

For Sep 2026, FREDUN PHARMACEUTICALS L (FREDUN) reported sales ₹268 Cr and net profit ₹19 Cr (figures in ₹ crore unless noted).

What are FREDUN annual sales and net profit?

For TTM, FREDUN PHARMACEUTICALS L (FREDUN) shows sales of ₹870 Cr and net profit of ₹54 Cr on the Fincrux profit & loss statement.

Who owns FREDUN PHARMACEUTICALS L (FREDUN)?

Latest shareholding for FREDUN PHARMACEUTICALS L (FREDUN) on Fincrux: Promoters 43.62% (Sep 2026), FIIs 0.69% (Sep 2026), DIIs 3.43% (Sep 2026), Public 52.25% (Sep 2026), No. of Shareholders 13,502% (Sep 2026).

Where can I find FREDUN PHARMACEUTICALS L (FREDUN) financials?

FREDUN PHARMACEUTICALS L (FREDUN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show FREDUN balance sheet and cash flow?

Yes. The FREDUN PHARMACEUTICALS L (FREDUN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.